Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) FCF Margin (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of FCF Margin data on record, last reported at 35.09% in Q3 2025.

  • For Q3 2025, FCF Margin rose 289.0% year-over-year to 35.09%; the TTM value through Dec 2025 reached 65.34%, up 4179.0%, while the annual FY2024 figure was 23.55%, 424.0% down from the prior year.
  • FCF Margin reached 35.09% in Q3 2025 per AMPH's latest filing, up from 387.85% in the prior quarter.
  • Across five years, FCF Margin topped out at 39.02% in Q2 2024 and bottomed at 387.85% in Q1 2025.
  • Average FCF Margin over 5 years is 0.67%, with a median of 26.23% recorded in 2024.
  • Peak YoY movement for FCF Margin: soared 4101bps in 2023, then plummeted -41491bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 27.76% in 2021, then plummeted by -64bps to 9.92% in 2022, then surged by 35bps to 13.42% in 2023, then tumbled by -128bps to 3.7% in 2024, then soared by 1049bps to 35.09% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 35.09% in Q3 2025, 387.85% in Q1 2025, and 3.7% in Q4 2024.